The immunohistochemical detection of steroid hormone receptors in breast cancer: Open problems and new perspectives

Pathologica

Volumn 94, Issue 3, 2002, Pages 115-120

  Barbareschi, M ^a   Doglioni, C ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Breast cancer; Immunohistochemistry; Quality control; Steroid hormone receptors; Therapy

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CHARCOAL; DEXTRAN; ESTROGEN RECEPTOR; ISOPROTEIN; PROGESTERONE RECEPTOR; REAGENT; STEROID RECEPTOR;

ANTIBODY DETECTION; ANTIGEN RETRIEVAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; EDITORIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; METHODOLOGY; PROGNOSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; TISSUE FIXATION; TREATMENT OUTCOME; VALIDATION PROCESS; BREAST TUMOR; FEMALE; METABOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0035984107     PISSN: 00312983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (45)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
2. Estrogen receptors and breast cancer response to adrenalectomy
3. Hormone-receptor interaction as a guide to biochemical mechanism
4. Mode of action of I.C.I. 46,474 in preventing implantation in rats
5. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
6. Estrogen receptors alpha and beta form heterodimers on DNA
7. Estrogen receptors alpha and beta: Two receptors of a kind?
8. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
9. Tamoxifen for early breast cancer: An overview of the randomised trials
10. Tamoxifen for patients with estrogen receptor-negative breast cancer
11. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors
12. Specific estrogen binding by the cytoplasm fof human breast carcinoma
13. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors
14. Immunocytochemical assay for estrogen receptor: Relationship to outcome of therapy in patients with advanced breast cancer
15. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
16. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
17. Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
18. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study
19. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance
20. Molecular markers for predicting response to tamoxifen in breast cancer patients
21. UK NEQAS for immunocytochemistry
22. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe
23. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening
24. Immunohistochemical demonstration of oestrogen and progesterone receptors: Correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries
25. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems
26. Estrogen receptor antibodies: Specificity and utility in detection, localization and analyses of estrogen receptor alpha and beta
27. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
28. Predictive value of ER1D5 antibody immunostaining in breast cancer
29. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: An immunohistochemical study on breast carcinoma with long-term follow-up
30. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: Comparison with biochemical determination in a prospective study of 793 cases
31. Oestrogen receptors and breast cancer
32. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method
33. Sequence and expression of human estrogen receptor complementary DNA
34. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique
35. ER beta: Identification and characterization of a novel human estrogen receptor
36. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer
37. Immunohistochemical detection of ERbeta in breast cancer: Towards more detailed receptor profiling
38. Clinical value of the wild-type estrogen receptor beta expression in breast cancer
39. Estrogen receptor beta expression in invasive breast cancer
40. Estrogen receptors and proliferation markers in primary and recurrent breast cancer
41. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients
42. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists
43. Detection of progesterone receptor forms A and B by immunohistochemical analysis
44. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol
45. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database